Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750508 | 0.78 | ALDH1A1 (0.50) | — | |
| SCHEMBL441463 | 0.76 | MAPK1 (0.33) | — | |
| SCHEMBL1712905 | 0.76 | KMT2A (0.41) | — | |
| SCHEMBL4000363 | 0.74 | CES2 (0.58) | — | |
| SCHEMBL4322089 | 0.72 | MAPK1 (0.32) | — | |
| SCHEMBL1713036 | 0.72 | ALDH1A1 (0.46) | — | |
| SCHEMBL1266916 | 0.72 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL1712644 | 0.72 | ABL1 (0.42) | — | |
| Methyl Alcohol SCHEMBL28939417 | 0.71 | CES2 (0.54) | — | |
| SCHEMBL5666673 | 0.71 | TSHR (0.59) | GABRA1GABRG2GABRB3GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118079019-A | Mitochondrial thermosensitive release nano preparation, preparation method and application thereof in preparation of deep tumor therapeutic drugs | 浙江中医药大学 | 2024-05-28 | — | — | CN | claimed |
| US-20240043529-A1 | METHODS AND COMPOSITIONS RELATED TO BCL2 AND BIM HETERODIMER ANTIBODIES | EUTROPICS PHARMACEUTICALS INC (US) | 2024-02-08 | — | — | US | claimed |
| US-20230330058-A1 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | Nuchido Limited (GB) | 2023-10-19 | — | — | US | claimed |
| WO-2023139263-A1 | PHENAZINE COMPOUND FOR MEASURING BACTERIAL EFFLUX | UNIVERSITE D'AIX-MARSEILLE (FR) | 2023-07-27 | — | — | WO | claimed |
| EP-4210656-A1 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | Nuchido Limited (GB) | 2023-07-19 | — | — | EP | claimed |
| CN-112899328-B | Method for synthesizing adenosine triphosphate by using yeast whole cell catalysis | 南京同凯兆业生物技术有限责任公司 | 2023-06-02 | — | — | CN | claimed |
| WO-2023010004-A1 | METHODS AND COMPOSITIONS RELATED TO MCL-1 AND BIM HETERODIMER ANTIBODIES | CARDONE MICHAEL H (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2022140556-A1 | METHODS AND COMPOSITIONS RELATED TO BCL2 AND BIM HETERODIMER ANTIBODIES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2022053800-A1 | SENOLYTIC COMPOUNDS AND COMPOSITIONS | Nuchido Limited (GB) | 2022-03-17 | — | — | WO | claimed |
| CN-112899328-A | Method for catalytically synthesizing adenosine triphosphate by using yeast whole cell | 南京同凯兆业生物技术有限责任公司 | 2021-06-04 | — | — | CN | claimed |
| WO-2013170176-A2 | SURROGATE FUNCTIONAL DIAGNOSTICS TEST FOR CANCER | EUTROPICS PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130096086-A1 | MITOCHONDRIA AND HUMAN IMMUNODEFIENCY VIRUS TYPE 1 | NEW YORK UNIVERSITY | 2013-04-18 | — | — | US | claimed |
| EP-2368112-A1 | LIVER CELL TOXICITY ASSAY | Corning Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| WO-2010065372-A1 | LIVER CELL TOXICITY ASSAY | CORNING INCORPORATED (US) | 2010-06-10 | — | — | WO | claimed |
| US-20100129854-A1 | LIVER CELL TOXICITY ASSAY | CORNING INCORPORATED | 2010-05-27 | — | — | US | claimed |
| EP-1104484-B1 | COMPOSITION AND METHODS FOR EXPOSING ANTIGENIC EPITOPES ON CULTURED MICROORGANISMS | BIOCONTROL SYSTEMS INC (US) | 2008-10-15 | — | — | EP | claimed |
| US-20020127699-A1 | Composition, formulae, devices and methods for control of specificity and inclusivity of microorganisms containing closely related antigen epitopes | BIOCONTROL SYSTEMS, INC. (US) | 2002-09-12 | — | — | US | claimed |
| EP-1104484-A2 | COMPOSITION AND METHODS FOR EXPOSING ANTIGENIC EPITOPES ON CULTURED MICROORGANISMS | BioControl Systems, Inc. (US) | 2001-06-06 | — | — | EP | claimed |
| CN-1254382-A | Bioluminescent reporter bacterium and methods for toxicity monitoring in biological wastewater treatment systems | EASTMAN CHEM CO (US) | 2000-05-24 | — | — | CN | claimed |
| WO-2000010013-A2 | COMPOSITION AND METHODS FOR EXPOSING ANTIGENIC EPITOPES ON CULTERED MICROORGANISM | BIOCONTROL SYSTEMS, INC. (US) | 2000-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096086-A1 | MITOCHONDRIA AND HUMAN IMMUNODEFIENCY VIRUS TYPE 1 | MAVS, MT-CO1, CYC1 | GABRA1 3749/4885GABRG2 4152/4885GABRB3 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.